Anti-Atherogenic Mechanisms and Therapies

Area of Science:

• Cardiovascular Research
• Immunology
• Molecular Biology

Background:

• Atherosclerosis is a chronic inflammatory disease.
• Impaired efferocytosis (clearance of apoptotic cells) exacerbates inflammation and plaque instability in atherosclerosis.
• Macrophage dysfunction and metabolic changes are central to the disease process.

Purpose of the Study:

• To review anti-atherogenic mechanisms, focusing on efferocytosis in inflammation resolution.
• To explore innovative, resolution-based therapeutic strategies for atherosclerosis.
• To highlight the link between macrophage metabolism, efferocytosis, and vascular homeostasis.

Main Methods:

• Review of current literature on atherosclerosis, inflammation, and efferocytosis.
• Analysis of molecular and cellular profiling data related to macrophage populations and metabolism.
• Examination of emerging therapeutic strategies, including pro-resolving mediators and vaccines.

Main Results:

• Impaired efferocytosis contributes to plaque instability and necrotic core expansion in atherosclerosis.
• Macrophage metabolic adaptations during efferocytosis are crucial for producing resolving mediators.
• Dysregulated signaling pathways and microRNAs negatively impact efferocytosis and cardiovascular outcomes.
• Resolution-based therapies and vaccines demonstrate potential for treating atherosclerosis by enhancing efferocytosis and modulating immune responses.

Conclusions:

• Efferocytosis is a critical regulator of inflammation resolution in atherosclerosis, connecting macrophage metabolism to plaque stability.
• Disruption of efferocytosis drives atherosclerosis progression, but novel therapies offer promising interventions.
• Advances in profiling and targeted delivery systems are key to developing precision medicine for atherosclerotic cardiovascular disease.